Search Result

Isoforms Recommended:	PDE3

Results for "

PDE3

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adenosine Receptor (4) Apoptosis (11) Autophagy (3) Endogenous Metabolite (7) HDAC (4) Histamine Receptor (3) Interleukin Related (4) Isotope-Labeled Compounds (6) MAPKAPK2 (MK2) (1) Phosphodiesterase (PDE) (54) PKA (3) RSV (4) Small Interfering RNA (siRNA) (4) TNF Receptor (4)
By Research Areas:	Cancer (19) Cardiovascular Disease (16) Endocrinology (5) Infection (2) Inflammation/Immunology (17) Metabolic Disease (8) Neurological Disease (8)

Inhibitors & Agonists

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-163285

PDE3B-IN-1

Phosphodiesterase (PDE) Metabolic Disease

PDE3B-IN-1 is a selective inhibitor for phosphodiesterase PDE3B with an IMAP pIC₅₀ of 6.5 and a PDE3B/A selective index >300 .

PDE3B-IN-1	Phosphodiesterase (PDE)	Metabolic Disease
PDE3B-IN-1 is a selective inhibitor for phosphodiesterase *PDE3B* with an IMAP pIC₅₀ of 6.5 and a PDE3B/A selective index >300 .

HY-RS10216

PDE3A Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)
PDE3A Human Pre-designed siRNA Set A contains three designed siRNAs for PDE3A gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PDE3A Human Pre-designed siRNA Set A PDE3A Human Pre-designed siRNA Set A

HY-RS10217

Pde3a Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)
Pde3a Mouse Pre-designed siRNA Set A contains three designed siRNAs for Pde3a gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Pde3a Mouse Pre-designed siRNA Set A Pde3a Mouse Pre-designed siRNA Set A

HY-RS10218

Pde3a Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)
Pde3a Rat Pre-designed siRNA Set A contains three designed siRNAs for Pde3a gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Pde3a Rat Pre-designed siRNA Set A Pde3a Rat Pre-designed siRNA Set A

HY-RS10219

PDE3B Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)
PDE3B Human Pre-designed siRNA Set A contains three designed siRNAs for PDE3B gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PDE3B Human Pre-designed siRNA Set A PDE3B Human Pre-designed siRNA Set A

HY-136350

BRD9500	Phosphodiesterase (PDE)	Cancer
BRD9500 is an orally active phosphodiesterases 3 (PDE3) inhibitor with IC₅₀s of 10 and 27 nM for *PDE3A* and *PDE3B*, respectively. Antitumor activity .

HY-14252

Milrinone

15+ Cited Publications

Win 47203
Phosphodiesterase (PDE) Cardiovascular Disease

Milrinone is a PDE3 inhibitor, and also an inotrope and vasodilator.

Milrinone 15+ Cited Publications Win 47203	Phosphodiesterase (PDE)	Cardiovascular Disease
Milrinone is a *PDE3* inhibitor, and also an inotrope and vasodilator.

HY-119708

Ensifentrine RPL-554	Phosphodiesterase (PDE)	Inflammation/Immunology
Ensifentrine (RPL-554) is an inhaled first-in-class dual inhibitor of phosphodiesterase 3 (PDE3) and *PDE4* with IC₅₀s of 0.4 nM and 1479 nM, respectively. Ensifentrine has bronchoprotective and anti-inflammatory activities. Ensifentrine can be used for chronic obstructive pulmonary disease (COPD) research .

HY-101312

Cilostamide 1 Publications Verification OPC3689
Cilostamide is a selective and potent *PDE3* inhibitor, with IC₅₀s of 27 nM and 50 nM for PDE3A and PDE3B, respectively, and has antithrombotic and anti-intimal hyperplastic activity.

HY-B0204

Pimobendan

2 Publications Verification

UD-CG115
Phosphodiesterase (PDE) Cardiovascular Disease

Pimobendan (UD-CG115) is a selective inhibitor of PDE3 with IC₅₀ of 0.32 μM.

Pimobendan 2 Publications Verification UD-CG115	Phosphodiesterase (PDE)	Cardiovascular Disease
Pimobendan (UD-CG115) is a selective inhibitor of PDE3 with IC₅₀ of 0.32 μM.

HY-B0204A

Pimobendan hydrochloride UD-CG115 hydrochloride	Phosphodiesterase (PDE)	Cardiovascular Disease
Pimobendan hydrochloride (UD-CG115 hydrochloride) is a selective inhibitor of PDE3 with IC₅₀ of 0.32 μM.

HY-14252S

Milrinone-d3	Isotope-Labeled Compounds Phosphodiesterase (PDE)	Cardiovascular Disease
Milrinone-d₃ is deuterium labeled Milrinone. Milrinone is a PDE3 inhibitor, and also an inotrope and vasodilator.

HY-19102

NSP-805	Phosphodiesterase (PDE)	Cardiovascular Disease
NSP-805 is a potent and selective inhibitor of guinea pig cardiac phosphodiesterase 3 (PDE3), and a cardiotonic agent with vasodilator properties.

HY-U00186

K134 OPC33509	Phosphodiesterase (PDE)	Cardiovascular Disease
K134 is a phosphodiesterase 3 (PDE3) inhibitor. The IC₅₀s of K134 toward *PDE3A, PDE3B, PDE5, PDE2 and PDE*4 are 0.1, 0.28, 12.1, >300 and >300 µM, respectively.

HY-B0523B

Anagrelide hydrochloride monohydrate	Phosphodiesterase (PDE) Apoptosis	Cardiovascular Disease Cancer
Anagrelide hydrochloride monohydrate is a potent inhibitor of phosphodiesterase type III (PDE3) (IC₅₀=36 nM). Anagrelide hydrochloride monohydrate, an imidazoquinazoline derivative, acts as an inhibitor of platelet aggregation. Anagrelide hydrochloride monohydrate inhibits bone marrow megakaryocytopoiesis. Anagrelide hydrochloride monohydrate decreases gastrointestinal stromal tumor (GIST) cell proliferation and promotes their apoptosis in vitro. Anagrelide hydrochloride monohydrate is a platelet-lowering agent and plays in the antithrombopoietic action ^[3].

HY-B0523A

Anagrelide hydrochloride 2 Publications Verification BL4162A	Phosphodiesterase (PDE) Apoptosis	Cardiovascular Disease Cancer
Anagrelide hydrochloride (BL4162A) is a potent inhibitor of phosphodiesterase type III (PDE3) (IC₅₀=36 nM). Anagrelide hydrochloride, an imidazoquinazoline derivative, acts as an inhibitor of platelet aggregation. Anagrelide hydrochloride inhibits bone marrow megakaryocytopoiesis. Anagrelide hydrochloride decreases gastrointestinal stromal tumor (GIST) cell proliferation and promotes their apoptosis in vitro. Anagrelide hydrochloride is a platelet-lowering agent and plays in the antithrombopoietic action ^[3].

HY-12318

IBMX Maximum Cited Publications 30 Publications Verification 3-Isobutyl-1-methylxanthine; Isobutylmethylxanthine	Phosphodiesterase (PDE)	Inflammation/Immunology
IBMX is a broad-spectrum phosphodiesterase (PDE) inhibitor, with IC₅₀s of 6.5, 26.3 and 31.7 μM for *PDE3, PDE4* and *PDE5*, respectively.

HY-136350B

(S)-BRD9500	Others	Cancer
(S)-BRD9500 is the inactive isomer of BRD9500 (HY-136350), and can be used as an experimental control. BRD9500 is an orally active phosphodiesterases 3 (PDE3) inhibitor with IC₅₀s of 10 and 27 nM for *PDE3A* and *PDE3B*, respectively. Antitumor activity .

HY-B1639

Enoximone	Phosphodiesterase (PDE)	Cardiovascular Disease Inflammation/Immunology
Enoximone is an inotropic vasodilating agent and a selective and orally active phosphodiesterase III (PDE3) inhibitor with an IC₅₀ of 5.9 μM. Enoximone induces vasodilatation and increases intracellular levels of cAMP by inhibiting cGMP-inhibited PDE. Enoximone also exhibits *PDE4* inhibitory effect with an IC₅₀ of 21.1 μM for myocardial PDE4A. Enoximone has the potential for congestive heart failure research and has bronchodilatory, antiasthma and anti-inflammatory effects ^[3].

HY-106477

Quazinone Ro 13-6438; Ro 13-6438/006	Phosphodiesterase (PDE) MAPKAPK2 (MK2)	Infection
Quazinone is a selective inhibitor of cGMP-inhibited-phosphodiesterase (cGI-PDE, PDE3). Quazinone inhibits the phosphorylation of p42/p44 MAP kinase. Quazinone possesses antimitogenic effect .

HY-109586

BRL-50481	Phosphodiesterase (PDE)	Neurological Disease
BRL-50481 is a novel and selective inhibitor of *PDE7* with IC₅₀s of 0.15, 12.1, 62 and 490 μM for *PDE7A, PDE7B, PDE4* and *PDE3*, respectively.

HY-111477

(E/Z)-Ensifentrine (E/Z)-RPL-554	Phosphodiesterase (PDE)	Neurological Disease
(E/Z)-Ensifentrine is a dual inhibitor of *PDE3/4*. (E/Z)-Ensifentrine reduces the inflammatory cells into the airways. (E/Z)-Ensifentrine has bronchodilatory and anti-inflammatory activities in vitro and in vivo model .

HY-106739

Motapizone NAT 05-239	Phosphodiesterase (PDE)	Inflammation/Immunology
Motapizone (NAT 05-239) is a selective *PDE3* inhibitor. Motapizone moderately inhibits cytokine release in lipopolysaccharide (LPS)-induced alveolar macrophages. Motapizone also inhibits human platelet aggregation by increasing intracellular cAMP .

HY-14254A

Olprinone Loprinone	Phosphodiesterase (PDE)	Cardiovascular Disease
Olprinone (Loprinone) is a potent phosphodiesterase (PDE) 3 inhibitor, with IC₅₀s of 150, 100, 0.35 and 14 μM for PDE1, PDE2, PDE3 and PDE4, respectively. Olprinone is used for the research of heart failure due to its positive inotropic and vasodilative effects. Anti-inflammatory activity .

HY-14254

Olprinone Hydrochloride Loprinone Hydrochloride	Phosphodiesterase (PDE)	Cardiovascular Disease
Olprinone (Loprinone) Hydrochloride is a potent phosphodiesterase (PDE) 3 inhibitor, with IC₅₀s of 150, 100, 0.35 and 14 μM for PDE1, PDE2, PDE3 and PDE4, respectively. Olprinone Hydrochloride is used for the research of heart failure due to its positive inotropic and vasodilative effects. Anti-inflammatory activity .

HY-105349

T-0156	Phosphodiesterase (PDE)	Neurological Disease
T-0156 is a potent and selective phosphodiesterase type 5 (PDE5) inhibitor. T-0156 specifically inhibits the hydrolysis of cyclic guanosine monophosphate (cGMP) by PDE5 in a competitive manner (IC₅₀=0.23 nM). T-0156 inhibits PDE6 (IC₅₀=56 nM) and has low potencies against PDE1, PDE2, PDE3, and PDE4 (IC₅₀>10 μM). T-0156 enhances the nitric oxide (NO)/cGMP pathway .

HY-15297

Vesnarinone 1 Publications Verification OPC-8212	Phosphodiesterase (PDE)	Infection Cardiovascular Disease
Vesnarinone (OPC-8212) is an orally active phosphodiesterase 3 (PDE3) inhibitor. Vesnarinone can increase in calcium flux and decrease in potassium flux. Vesnarinone shows dose-dependent positive inotropic activity. Vesnarinone can be used in heart failure research ^[3] .

HY-102050

PF-05085727	Phosphodiesterase (PDE)	Neurological Disease
PF-05085727 is a potent, selective and brain penetrant inhibitor of cGMP-dependent *PDE2A* (IC₅₀=2 nM). PF-05085727 inhibits PDE2A >4,000-fold selectivity over PDE1 and PDE3-11 .

HY-15455

Roflumilast 5+ Cited Publications APTA-2217; BYK 20869; B9302-107	Phosphodiesterase (PDE) RSV	Inflammation/Immunology
Roflumilast (APTA-2217) is a selective *PDE4* inhibitor with IC₅₀s of 0.7, 0.9, 0.7, and 0.2 nM for *PDE4A1, PDEA4, PDEB1, and PDEB2, respectively, without affecting PDE1, PDE2, PDE3* or PDE5 isoenzymes from various cells.

HY-B0523

Anagrelide	Phosphodiesterase (PDE) Apoptosis	Cardiovascular Disease Cancer
Anagrelide is a potent inhibitor of phosphodiesterase type III (PDE3) (IC₅₀=36 nM). Anagrelide, an imidazoquinazoline derivative, acts as an inhibitor of platelet aggregation. Anagrelide inhibits bone marrow megakaryocytopoiesis. Anagrelide decreases gastrointestinal stromal tumor (GIST) cell proliferation and promotes their apoptosis in vitro. Anagrelide is a platelet-lowering agent and plays in the antithrombopoietic action ^[3].

HY-15455S2

Roflumilast-d3 APTA-2217-d₃; BYK 20869-d₃; B9302-107-d₃	Isotope-Labeled Compounds Phosphodiesterase (PDE) RSV	Inflammation/Immunology
Roflumilast-d₃ is deuterium labeled Roflumilast. Roflumilast is a selective PDE4 inhibitor with IC50s of 0.7, 0.9, 0.7, and 0.2 nM for PDE4A1, PDEA4, PDEB1, and PDEB2, respectively, without affecting PDE1, PDE2, PDE3 or PDE5 isoenzymes from various cells.

HY-A0027

Fenspiride hydrochloride	Histamine Receptor Phosphodiesterase (PDE)	Inflammation/Immunology Endocrinology
Fenspiride, an orally active non-steroidal antiinflammatory agent, is an antagonist of H1-histamine receptor. Fenspiride inhibites phosphodiesterase 3 (PDE3), phosphodiesterase 4 (PDE4) and phosphodiesterase 5 (PDE5) activities with -log IC₅₀ values of 3.44, 4.16 and approximately 3.8, respectively. Fenspiride can be used for the research of respiratory diseases ^[3].

HY-A0027A

Fenspiride	Histamine Receptor Phosphodiesterase (PDE)	Inflammation/Immunology
Fenspiride, an orally active non-steroidal antiinflammatory agent, is an antagonist of H1-histamine receptor. Fenspiride inhibites phosphodiesterase 3 (PDE3), phosphodiesterase 4 (PDE4) and phosphodiesterase 5 (PDE5) activities with -log IC₅₀ values of 3.44, 4.16 and approximately 3.8, respectively. Fenspiride can be used for the research of respiratory diseases ^[3].

HY-15455S

Roflumilast-d4 APTA-2217-d₄; BYK 20869-d₄; B9302-107-d₄	Isotope-Labeled Compounds Phosphodiesterase (PDE) RSV	Inflammation/Immunology
Roflumilast-d₄ is the deuterium labeled Roflumilast. Roflumilast is a selective PDE4 inhibitor with IC50s of 0.7, 0.9, 0.7, and 0.2 nM for PDE4A1, PDEA4, PDEB1, and PDEB2, respectively, without affecting PDE1, PDE2, PDE3 or PDE5 isoenzymes from various cells[1][2].

HY-15455S1

Roflumilast-d4 N-Oxide	Phosphodiesterase (PDE) RSV	Inflammation/Immunology
Roflumilast-d₄ N-Oxide is the deuterium labeled Roflumilast. Roflumilast is a selective PDE4 inhibitor with IC50s of 0.7, 0.9, 0.7, and 0.2 nM for PDE4A1, PDEA4, PDEB1, and PDEB2, respectively, without affecting PDE1, PDE2, PDE3 or PDE5 isoenzymes from various cells[1][2].

HY-15485

Zardaverine	Phosphodiesterase (PDE) Apoptosis	Inflammation/Immunology Cancer
Zardaverine is an orally active and selective *PDE3/4* inhibitor (IC₅₀)=0.58 uM/0.17 uM) with potent bronchodilator activity. Zardaverine also selectively inhibits the proliferation of HCC cells and induces apoptosis and cycle arrest (G0/G1 phase). Zardaverine has good antitumor potential and is effective in both bronchial relaxation and reduction of inflammation in asthma ^[3].

HY-B0442

Vardenafil 2 Publications Verification	Phosphodiesterase (PDE) Endogenous Metabolite	Metabolic Disease Inflammation/Immunology Endocrinology
Vardenafil is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC₅₀ of 0.7 nM. Vardenafil shows inhibitory towards PDE1, PDE6 with IC₅₀s of 180 nM, and 11 nM, while IC₅₀s are >1000 nM for PDE3 and PDE4 . Vardenafil competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil can be used for the research of erectile dysfunction, hepatitis, diabetes ^[1]-[6].

HY-B0442A

Vardenafil hydrochloride 2 Publications Verification	Phosphodiesterase (PDE) Endogenous Metabolite	Metabolic Disease Inflammation/Immunology Endocrinology
Vardenafil hydrochloride is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC₅₀ of 0.7 nM. Vardenafil hydrochloride shows inhibitory towards PDE1, PDE6 with IC₅₀s of 180 nM, and 11 nM, while IC₅₀s are >1000 nM for PDE3 and PDE4 . Vardenafil hydrochloride competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil hydrochloride can be used for the research of erectile dysfunction, hepatitis, diabetes ^[1]-[6].

HY-A0027AS

Fenspiride-d5	Isotope-Labeled Compounds Histamine Receptor Phosphodiesterase (PDE)	Inflammation/Immunology
Fenspiride-d₅ is the deuterium labeled Fenspiride. Fenspiride, an orally active non-steroidal antiinflammatory agent, is an antagonist of H1-histamine receptor. Fenspiride inhibites phosphodiesterase 3 (PDE3), phosphodiesterase 4 (PDE4) and phosphodiesterase 5 (PDE5) activities with -log IC50 values of 3.44, 4.16 and approximately 3.8, respectively. Fenspiride can be used for the research of respiratory diseases[1][2][3].

HY-B0442S

Vardenafil-d5	Phosphodiesterase (PDE) Endogenous Metabolite	Endocrinology
Vardenafil-d₅ is deuterium labeled Vardenafil. Vardenafil is a selective, orally active, potent inhibitor of phosphodiesterase-5 (PDE5), with an IC50 of 0.7 nM. Vardenafil shows selectivity over PDE1 (180 nM), PDE6 (11 nM), PDE2, PDE3, and PDE4 (>1000 nM). Vardenafil competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Vardenafil can be used for the research of erectile dysfunction[1][2].

HY-B0442C

Vardenafil dihydrochloride	Endogenous Metabolite Phosphodiesterase (PDE)	Metabolic Disease Inflammation/Immunology Endocrinology
Vardenafil dihydrochloride is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC₅₀ of 0.7 nM. Vardenafil dihydrochloride shows inhibitory towards PDE1, PDE6 with IC₅₀s of 180 nM, and 11 nM respectively, while IC₅₀s are >1000 nM for PDE3 and PDE4. Vardenafil dihydrochloride competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Vardenafil dihydrochloride can be used for the research of erectile dysfunction, hepatitis, diabetes ^- .

HY-107909

Theophylline sodium glycinate 1,3-Dimethylxanthine sodium glycinate; Theo-24 sodium glycinate	Adenosine Receptor HDAC Apoptosis Interleukin Related TNF Receptor	Cancer
Theophylline (1,3-Dimethylxanthine) sodium glycinate is a potent phosphodiesterase (PDE) inhibitor, adenosine receptor antagonist, and histone deacetylase (HDAC) activator. Theophylline sodium glycinate inhibits PDE3 activity to relax airway smooth muscle. Theophylline sodium glycinate has anti-inflammatory activity by increase IL-10 and inhibit NF-κB into the nucleus. Theophylline sodium glycinate induces apoptosis. Theophylline sodium glycinate can be used for asthma and chronic obstructive pulmonary disease (COPD) research ^[3] .

HY-B0442B

Vardenafil hydrochloride trihydrate 1 Publications Verification
Vardenafil hydrochloride trihydrate is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC₅₀ of 0.7 nM. Vardenafil hydrochloride trihydrate shows inhibitory towards PDE1, PDE6 with IC₅₀s of 180 nM, and 11 nM, while IC₅₀s are >1000 nM for PDE3 and PDE4 . Vardenafil hydrochloride trihydrate competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil hydrochloride trihydrate can be used for the research of erectile dysfunction, hepatitis, diabetes ^[1]-[6].

HY-10790

Cilomilast 1 Publications Verification SB-207499	Phosphodiesterase (PDE)	Inflammation/Immunology
Cilomilast (SB-207499) is a potent, selective and orally active inhibitor of Phosphodiesterase 4 (PDE4), with IC₅₀s of ~100 and 120 nM for LPDE4 and HPDE4, respectively. Cilomilast shows selectivity for PDE4 over PDE1, PDE2, PDE3 and PDE5 (IC₅₀=74, 65, >100, and 83 µM, respectively). Cilomilast has anti-inflammatory and immunomodulatory effects and can be used for thr research of asthma and chronic obstructive pulmonary disease (COPD) ^[3].

HY-B0809

Theophylline 5+ Cited Publications 1,3-Dimethylxanthine; Theo-24	Phosphodiesterase (PDE) Adenosine Receptor HDAC Apoptosis Interleukin Related TNF Receptor Endogenous Metabolite	Cancer
Theophylline (1,3-Dimethylxanthine) is a potent phosphodiesterase (PDE) inhibitor, adenosine receptor antagonist, and histone deacetylase (HDAC) activator. Theophylline (1,3-Dimethylxanthine) inhibits PDE3 activity to relax airway smooth muscle. Theophylline (1,3-Dimethylxanthine) has anti-inflammatory activity by increase IL-10 and inhibit NF-κB into the nucleus. Theophylline (1,3-Dimethylxanthine) induces apoptosis. Theophylline (1,3-Dimethylxanthine) can be used for asthma and chronic obstructive pulmonary disease (COPD) research ^[3] .

HY-B0809B

Theophylline sodium acetate 1,3-Dimethylxanthine sodium acetate; Theo-24 sodium acetate	Endogenous Metabolite Phosphodiesterase (PDE) Adenosine Receptor HDAC Apoptosis Interleukin Related TNF Receptor	Cancer
Theophylline (1,3-Dimethylxanthine) sodium acetate is a potent phosphodiesterase (PDE) inhibitor, adenosine receptor antagonist, and histone deacetylase (HDAC) activator. Theophylline (1,3-Dimethylxanthine) sodium acetate inhibits PDE3 activity to relax airway smooth muscle. Theophylline (1,3-Dimethylxanthine) sodium acetate has anti-inflammatory activity by increase IL-10 and inhibit NF-κB into the nucleus. Theophylline (1,3-Dimethylxanthine) sodium acetate induces apoptosis. Theophylline (1,3-Dimethylxanthine) sodium acetate can be used for asthma and chronic obstructive pulmonary disease (COPD) research ^[3] .

HY-B0809A

Theophylline monohydrate 1,3-Dimethylxanthine monohydrate; Theo-24 monohydrate
Theophylline (1,3-Dimethylxanthine) monohydrate is a potent phosphodiesterase (PDE) inhibitor, adenosine receptor antagonist, and histone deacetylase (HDAC) activator. Theophylline (1,3-Dimethylxanthine) monohydrate inhibits PDE3 activity to relax airway smooth muscle. Theophylline (1,3-Dimethylxanthine) monohydrate has anti-inflammatory activity by increase IL-10 and inhibit NF-κB into the nucleus. Theophylline (1,3-Dimethylxanthine) monohydrate induces apoptosis. Theophylline (1,3-Dimethylxanthine) monohydrate can be used for asthma and chronic obstructive pulmonary disease (COPD) research ^[3] .

HY-B0809R

Theophylline (Standard) 1,3-Dimethylxanthine(Standard); Theo-24 (Standard)	Phosphodiesterase (PDE) Adenosine Receptor HDAC Apoptosis Interleukin Related TNF Receptor Endogenous Metabolite	Cancer
Theophylline (Standard) is the analytical standard of Theophylline. This product is intended for research and analytical applications. Theophylline (1,3-Dimethylxanthine) is a potent phosphodiesterase (PDE) inhibitor, adenosine receptor antagonist, and histone deacetylase (HDAC) activator. Theophylline (1,3-Dimethylxanthine) inhibits PDE3 activity to relax airway smooth muscle. Theophylline (1,3-Dimethylxanthine) has anti-inflammatory activity by increase IL-10 and inhibit NF-κB into the nucleus. Theophylline (1,3-Dimethylxanthine) induces apoptosis. Theophylline (1,3-Dimethylxanthine) can be used for asthma and chronic obstructive pulmonary disease (COPD) research ^[3] .

HY-145924

BAY 2666605 1 Publications Verification	Phosphodiesterase (PDE)	Cancer
BAY 2666605 is an orally active *PDE3A* and *PDE3B* inhibitor with IC₅₀s of 87 nM and 50 nM, respectively. BAY 2666605 is a *PDE3A-SLFN12* complex inducer (WO2019025562A1; example 135) .

HY-N10149

Nauclefine	Phosphodiesterase (PDE) Apoptosis	Cancer
Nauclefine is an indole alkaloid isolated from Nauclea officinalis. Nauclefine acts as a *PDE3A* modulator to induce cancer cell apoptosis through a PDE3A-SLFN12-dependent death pathway .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-A0027

Fenspiride hydrochloride	Classification of Application Fields Disease Research Fields Endocrinology	Histamine Receptor Phosphodiesterase (PDE)
Fenspiride, an orally active non-steroidal antiinflammatory agent, is an antagonist of H1-histamine receptor. Fenspiride inhibites phosphodiesterase 3 (PDE3), phosphodiesterase 4 (PDE4) and phosphodiesterase 5 (PDE5) activities with -log IC₅₀ values of 3.44, 4.16 and approximately 3.8, respectively. Fenspiride can be used for the research of respiratory diseases ^[3].

HY-B0442

Vardenafil 2 Publications Verification	Structural Classification Natural Products Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields Endocrinology	Phosphodiesterase (PDE) Endogenous Metabolite
Vardenafil is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC₅₀ of 0.7 nM. Vardenafil shows inhibitory towards PDE1, PDE6 with IC₅₀s of 180 nM, and 11 nM, while IC₅₀s are >1000 nM for PDE3 and PDE4 . Vardenafil competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil can be used for the research of erectile dysfunction, hepatitis, diabetes ^[1]-[6].

HY-B0442A

Vardenafil hydrochloride 2 Publications Verification	Structural Classification Natural Products Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields Endocrinology	Phosphodiesterase (PDE) Endogenous Metabolite
Vardenafil hydrochloride is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC₅₀ of 0.7 nM. Vardenafil hydrochloride shows inhibitory towards PDE1, PDE6 with IC₅₀s of 180 nM, and 11 nM, while IC₅₀s are >1000 nM for PDE3 and PDE4 . Vardenafil hydrochloride competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil hydrochloride can be used for the research of erectile dysfunction, hepatitis, diabetes ^[1]-[6].

HY-B0809

Theophylline Maximum Cited Publications 6 Publications Verification 1,3-Dimethylxanthine; Theo-24	Structural Classification Classification of Application Fields Source classification Plants Camellia sinensis (L.) O. Ktze. Endogenous metabolite Alkaloids Microorganisms Immune System Disorder Disease markers Disease Research Fields Cancer Theaceae	Phosphodiesterase (PDE) Adenosine Receptor HDAC Apoptosis Interleukin Related TNF Receptor Endogenous Metabolite
Theophylline (1,3-Dimethylxanthine) is a potent phosphodiesterase (PDE) inhibitor, adenosine receptor antagonist, and histone deacetylase (HDAC) activator. Theophylline (1,3-Dimethylxanthine) inhibits PDE3 activity to relax airway smooth muscle. Theophylline (1,3-Dimethylxanthine) has anti-inflammatory activity by increase IL-10 and inhibit NF-κB into the nucleus. Theophylline (1,3-Dimethylxanthine) induces apoptosis. Theophylline (1,3-Dimethylxanthine) can be used for asthma and chronic obstructive pulmonary disease (COPD) research ^[3] .

HY-B0442C

Vardenafil dihydrochloride	Structural Classification Natural Products Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields Endocrinology	Endogenous Metabolite Phosphodiesterase (PDE)
Vardenafil dihydrochloride is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC₅₀ of 0.7 nM. Vardenafil dihydrochloride shows inhibitory towards PDE1, PDE6 with IC₅₀s of 180 nM, and 11 nM respectively, while IC₅₀s are >1000 nM for PDE3 and PDE4. Vardenafil dihydrochloride competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Vardenafil dihydrochloride can be used for the research of erectile dysfunction, hepatitis, diabetes ^- .

HY-B0809B

Theophylline sodium acetate 1,3-Dimethylxanthine sodium acetate; Theo-24 sodium acetate	Structural Classification Natural Products Classification of Application Fields Source classification Endogenous metabolite Disease Research Fields Cancer	Endogenous Metabolite Phosphodiesterase (PDE) Adenosine Receptor HDAC Apoptosis Interleukin Related TNF Receptor
Theophylline (1,3-Dimethylxanthine) sodium acetate is a potent phosphodiesterase (PDE) inhibitor, adenosine receptor antagonist, and histone deacetylase (HDAC) activator. Theophylline (1,3-Dimethylxanthine) sodium acetate inhibits PDE3 activity to relax airway smooth muscle. Theophylline (1,3-Dimethylxanthine) sodium acetate has anti-inflammatory activity by increase IL-10 and inhibit NF-κB into the nucleus. Theophylline (1,3-Dimethylxanthine) sodium acetate induces apoptosis. Theophylline (1,3-Dimethylxanthine) sodium acetate can be used for asthma and chronic obstructive pulmonary disease (COPD) research ^[3] .

HY-B0809R

Theophylline (Standard) 1,3-Dimethylxanthine(Standard); Theo-24 (Standard)	Structural Classification Alkaloids Immune System Disorder Classification of Application Fields Source classification Disease markers Plants Camellia sinensis (L.) O. Ktze. Endogenous metabolite Disease Research Fields Cancer Theaceae	Phosphodiesterase (PDE) Adenosine Receptor HDAC Apoptosis Interleukin Related TNF Receptor Endogenous Metabolite
Theophylline (Standard) is the analytical standard of Theophylline. This product is intended for research and analytical applications. Theophylline (1,3-Dimethylxanthine) is a potent phosphodiesterase (PDE) inhibitor, adenosine receptor antagonist, and histone deacetylase (HDAC) activator. Theophylline (1,3-Dimethylxanthine) inhibits PDE3 activity to relax airway smooth muscle. Theophylline (1,3-Dimethylxanthine) has anti-inflammatory activity by increase IL-10 and inhibit NF-κB into the nucleus. Theophylline (1,3-Dimethylxanthine) induces apoptosis. Theophylline (1,3-Dimethylxanthine) can be used for asthma and chronic obstructive pulmonary disease (COPD) research ^[3] .

HY-N10149

Nauclefine	Structural Classification Alkaloids Nauclea officinalis (Pirre ex Pitard) Merr. Source classification Rubiaceae Plants Indole Alkaloids	Phosphodiesterase (PDE) Apoptosis
Nauclefine is an indole alkaloid isolated from Nauclea officinalis. Nauclefine acts as a *PDE3A* modulator to induce cancer cell apoptosis through a PDE3A-SLFN12-dependent death pathway .

HY-N11965

4'-Methoxyisoagarotetrol	Structural Classification Natural Products Thymelaeaceae Source classification Plants Aquilaria sinensis (Lour.) Spreng.	Phosphodiesterase (PDE)
4'-Methoxyisoagarotetrol is chromone derivative and shows moderate *PDE?3A* inhibitory activity (IC₅₀=54 μM) .

Cat. No.	Product Name	Chemical Structure

HY-15455S1

Roflumilast-d4 N-Oxide
Roflumilast-d₄ N-Oxide is the deuterium labeled Roflumilast. Roflumilast is a selective PDE4 inhibitor with IC50s of 0.7, 0.9, 0.7, and 0.2 nM for PDE4A1, PDEA4, PDEB1, and PDEB2, respectively, without affecting PDE1, PDE2, PDE3 or PDE5 isoenzymes from various cells[1][2].

HY-14252S

Milrinone-d3

Milrinone-d₃ is deuterium labeled Milrinone. Milrinone is a PDE3 inhibitor, and also an inotrope and vasodilator.

HY-15455S2

Roflumilast-d3
Roflumilast-d₃ is deuterium labeled Roflumilast. Roflumilast is a selective PDE4 inhibitor with IC50s of 0.7, 0.9, 0.7, and 0.2 nM for PDE4A1, PDEA4, PDEB1, and PDEB2, respectively, without affecting PDE1, PDE2, PDE3 or PDE5 isoenzymes from various cells.

HY-15455S

Roflumilast-d4
Roflumilast-d₄ is the deuterium labeled Roflumilast. Roflumilast is a selective PDE4 inhibitor with IC50s of 0.7, 0.9, 0.7, and 0.2 nM for PDE4A1, PDEA4, PDEB1, and PDEB2, respectively, without affecting PDE1, PDE2, PDE3 or PDE5 isoenzymes from various cells[1][2].

HY-A0027AS

Fenspiride-d5

Fenspiride-d₅ is the deuterium labeled Fenspiride. Fenspiride, an orally active non-steroidal antiinflammatory agent, is an antagonist of H1-histamine receptor. Fenspiride inhibites phosphodiesterase 3 (PDE3), phosphodiesterase 4 (PDE4) and phosphodiesterase 5 (PDE5) activities with -log IC50 values of 3.44, 4.16 and approximately 3.8, respectively. Fenspiride can be used for the research of respiratory diseases[1][2][3].

HY-B0442S

Vardenafil-d5

Vardenafil-d₅ is deuterium labeled Vardenafil. Vardenafil is a selective, orally active, potent inhibitor of phosphodiesterase-5 (PDE5), with an IC50 of 0.7 nM. Vardenafil shows selectivity over PDE1 (180 nM), PDE6 (11 nM), PDE2, PDE3, and PDE4 (>1000 nM). Vardenafil competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Vardenafil can be used for the research of erectile dysfunction[1][2].

HY-17464S

Cilostazol-d11
Cilostazol-d₁₁ is the deuterium labeled Cilostazol. Cilostazol (OPC 13013) is a potent and selective inhibitor of phosphodiesterase (PDE) 3A, the isoform of PDE 3 in the cardiovascular system, with an IC50 of 0.2 μM[1][2].

HY-17464S1

Cilostazol-d4
Cilostazol-d₄ is deuterium labeled Cilostazol. Cilostazol (OPC 13013) is a potent and selective inhibitor of phosphodiesterase (PDE) 3A, the isoform of PDE 3 in the cardiovascular system, with an IC50 of 0.2 μM[1][2].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks